crospovidone.

In the present study, novel co-processed superdisintegrants were developed by solvent evaporation method using crospovidone and croscarmellose sodium in the different ratios (1:1, 1:2 & 1:3) to formulate mouth dissolving tablet formulations of Meloxicam. The poor aqueous solubility of Meloxicam makes its absorption as dissolution rate-limited and thus delay onset of action. Mouth dissolving tablets of Meloxicam were prepared using the above co-processed superdisintegrants and evaluated for different parameters. Effect of co-processed superdisintegrants (such as crospovidone and sodium starch glycolate) on wetting time, disintegrating time, drug content and in-vitro release parameters have been studied. Based on in vitro dispersion time (approximately 19 sec), promising formulation CP1 was tested for in-vitro drug release pattern. Among the designed formulations, the formulation (CP1) containing 4% w/w of co-processed superdisintegrant (1:1 mixture of crospovidone and sodium starch glycolate) found as the best formulation based on drug release characteristics. From this study, it can be concluded that dissolution rate of Meloxicam could be enhanced by tablets containing co-processed superdisintegrant.